Document:

NONQUALIFIED STOCK OPTION AGREEMENT

     NONQUALIFIED  STOCK OPTION  AGREEMENT,  dated as of August 9, 2000,  by and
between, Empyrean Bioscience,  Inc., a Wyoming corporation (the "Company"),  and
International Bioscience Corporation, a Florida corporation (the "Optionee").

                              W I T N E S S E T H:

     WHEREAS,  the  Company  and the  Optionee  are  parties to a Joint  Venture
Agreement dated August 9, 2000 which  contemplates  that the Company will, among
other  matters  and in order to  induce  the  Optionee  to enter  into the Joint
Venture Agreement,  issue to the Optionee an option to acquire certain shares of
the Company's  Common Stock, no par value, on the terms and conditions set forth
in this Agreement;

     NOW,  THEREFORE,  in  consideration  of the  premises  and  of  the  mutual
agreements contained in this Agreement, the parties hereto agree as follows:

     1.  Definitions.  As used in this  Agreement,  the following terms have the
meanings set forth below:

          "Act" shall mean the Securities Act of 1933, as amended.

          "Affiliate"  when used with  reference  to any Person,  shall mean any
other Person that directly,  or indirectly  through one or more  intermediaries,
controls,  is  controlled  by,  or is under  common  control  with,  the  Person
specified.

          "Board" shall mean the board of directors of the Company.

          "Common  Stock"  shall mean the shares of Common Stock of the Company,
no par value.

          "Contemplated Agreements" shall mean the following agreements dated as
of August 9, 2000: (i) the Trademark  License  Agreement from the Company to the
Optionee; (ii) the Trademark License Agreement from the Company to IBC-Empyrean,
L.L.C.;  (iii) the License Agreement from the Optionee to the Company;  (iv) the
Trademark  License  Agreement from the Optionee to the Company;  (v) the License
Agreement from the Optionee to IBC-Empyrean,  L.L.C.; (vi) the Trademark License
Agreement  from the Optionee to  IBC-Empyrean,  L.L.C.;  (vii) the Joint Venture
Agreement between the Company and the Optionee (the "Joint Venture  Agreement");
(viii) the Limited Liability Company Agreement of IBC-Empyrean, L.L.C.; (ix) the
Put Agreement between the Company and the Optionee; and (x) the Voting Agreement
between the Optionee and Lawrence D. Bain (the "Voting Agreement").

          "Derivative Products" shall mean products hereinafter developed by the
Optionee  having an  effective  amount of  Formulation  therein,  and being of a
different  product  category  than  those  Licensed  Products   currently  being
manufactured.
<PAGE>
          "Exercise  Price"  shall  have the  meaning  ascribed  to such term in
Section 2 of this Agreement.

          "Fair Market Value" of a share of Common Stock on any date shall mean,
(i) if the Common Stock is listed on a national stock  exchange,  the officially
quoted closing price on such stock exchange,  (ii) if the Common Stock is listed
on the NASDAQ National  Market,  the officially  quoted closing price on NASDAQ,
(iii) if the Common  Stock is listed on NASDAQ but not on the  National  Market,
the average of the closing bid and asked prices reported by NASDAQ, in each case
on the date as of which the value is to be determined  (or if such date is not a
trading  day, as of the  preceding  trading  day),  (iv) if the Common  Stock is
listed on an over-the-counter  market, the average of the last bid prices on the
date as of which the value is to be determined (or if such date is not a trading
day, as of the  preceding  trading day) or (v) if the Common Stock is not listed
on either a national stock exchange or NASDAQ,  the fair market value determined
in good faith by the Board.

          "Formulation"  shall  mean  the  proprietary   formulation  (including
manufacturing  technology and processes) comprising  Benzalkonium Chloride as an
active  ingredient  with  Octoxynol 9 (and  others)  invented and created by Dr.
David Thornburgh and exclusively owned by the Optionee known as the GEDA line of
products.

          "GEDA  Plus  Product"  shall  mean  the  spermicide  and   microbicide
contraceptive gel product embodying the Formulation presently being developed by
the  Optionee,  also  known  as the  "Gel  Product",  designed  to  prevent  the
transmission of sexually  transmitted  diseases  including,  but not limited to,
gonorrhea,  chlamydia, syphilis, Trichomonas, herpes I and II and HIV, and which
is presently undergoing the appropriate and necessary United States governmental
regulatory compliance process to permit the Company to include such product as a
Licensed Product.

          "Licensed  Products" shall mean products having an effective amount of
the  Formulation  therein  and  having all  necessary  government  approval  for
commercialization,  including,  but not limited to, the Lotion Products, the Gel
Product and any Derivative Products hereinafter developed by the Optionee.

          "Lotion  Products"  (also  known as GEDA  Lotion)  shall mean the hand
sanitizing  lotion  presently  being  manufactured  for the  Company by Canadian
Custom  Packaging and sold by the Company as a Licensed  Product,  and presently
being  marketed by the Company under  appropriate  and  necessary  United States
governmental regulatory compliance.

          "Option" shall have the meaning set forth in Section 2 hereof.

          "Person"  shall  mean  any  individual,   limited  liability  company,
partnership, corporation, group, trust or other legal entity.

     2.  Grant  of  Option;  Option  Price.  On the  terms  and  subject  to the
conditions  of this  Agreement,  the Company  hereby  grants to the Optionee the
option (the  "Option") to purchase an  aggregate  of 2,226,000  shares of Common

                                       2
<PAGE>
Stock  (the  "Option  Shares")  at an  exercise  price  of $.83 per  share  (the
"Exercise Price").

     3. Term.  The term of the Option (the "Option  Term") shall commence on the
date hereof and expire on the tenth  anniversary of the date hereof,  unless the
Option shall  theretofore  have been  terminated in accordance with the terms of
this Agreement.

     4.  Vesting and  Exercisability.  The right to acquire the shares of Common
Stock (the "Shares") represented by this Option shall vest as follows, and shall
otherwise be exercisable in accordance with the following terms and conditions:

          (i)  1,000,000 of the Option  Shares may be purchased  upon receipt of
the  pre-IND  number  from the Food and Drug  Administration  for the GEDA  Plus
Product;

          (ii)  1,000,000 of the Option Shares may be purchased upon delivery of
the towlettes  presently being  manufactured  with agreed upon claims for retail
distribution; and

          (iii) the remaining 226,000 Option Shares may be immediately purchased
upon execution of the Contemplated Agreements.

     5. Procedure for Exercise.

          (a) The  Option  may be  exercised  with  respect  to Shares  that are
exercisable,  from time to time,  in whole or in part (but for the  purchase  of
whole Shares only), by delivery of a written notice (the "Exercise Notice") from
the Optionee to the Company at its principal  executive  office,  which Exercise
Notice shall:

               (i) state that the Optionee elects to exercise the Option;

               (ii)  specify  the  number of Shares  with  respect  to which the
Optionee is exercising the Option;

               (iii) include any  representations of the Optionee required under
Section 7 hereof;

               (iv) state the date upon which the Optionee desires to consummate
the purchase of such Shares (which date must be prior to the  termination of the
Option);

               (v) state the payment method for the exercise of the Option; and

               (vi)  comply  with such  further  provisions  as the  Company may
reasonably require.

          (b) Payment of the  Exercise  Price for the Shares to be  purchased on
the exercise of the Option  shall be made by cash or check  payable to the order
of the Company.  Notwithstanding  the  foregoing,  the  Optionee  shall have the
right, subject to the Company's approval (in its sole discretion), to receive in

                                       3
<PAGE>
lieu of the Shares an amount in cash from the  Company  equal to the  difference
between the Fair Market Value of the Shares to be received  upon the exercise of
the Option and the Exercise Price therefore.

          (c) The  Company  shall be  entitled  to  require  as a  condition  of
delivery  of the Shares that the  Optionee  agree to remit when due an amount in
cash sufficient to satisfy all current or estimated  future  federal,  state and
local withholding and employment taxes relating thereto.

     6. Rights as a  Stockholder.  The Optionee's  rights as a stockholder  upon
exercise of the Option Shares shall be subject to the Voting Agreement.

     7. Registration of Shares and Additional Provisions Related to Exercise.

          (a) The  registration of the Common Stock underlying the Option Shares
and the  registration  rights of the  Optionee  are  subject to Section 7 of the
Joint Venture Agreement.

          (b) In the event of the exercise of the Option at a time when there is
not in effect a  registration  statement  under the  Securities  Act of 1933, as
amended (the "Act"),  relating to the Shares, the Optionee hereby represents and
warrants,  and by virtue of such  exercise  shall be  deemed  to  represent  and
warrant,  to the Company that the Shares are being acquired for investment  only
and not with a view to the  distribution  thereof except in compliance with such
Act,   and  the   Optionee   shall   provide  the  Company   with  such  further
representations  and warranties as the Board may reasonably  require in order to
ensure compliance with applicable  federal and state securities,  "blue sky" and
other laws. No Shares shall be purchased  upon the exercise of the Option unless
and  until  the  Company  and/or  the  Optionee  shall  have  complied  with all
applicable  federal  or  state   registration,   listing  and/or   qualification
requirements  and all other  requirements  of law or of any regulatory  agencies
having jurisdiction.

     8.  Restriction on Transfer.  The Option may not be  transferred,  pledged,
assigned,  hypothecated or otherwise  disposed of in any way by the Optionee and
may be  exercised  only by the  Optionee.  The  Option  shall not be  subject to
execution,  attachment or similar process. Any attempted  assignment,  transfer,
pledge,  hypothecation  or  other  disposition  of the  Option  contrary  to the
provisions hereof, and the levy of any execution,  attachment or similar process
upon the Option, shall be null and void and without effect.

     9. Adjustment.

          (a) If the Shares are changed,  or the number of Shares outstanding is
increased or diminished,  by reason of a stock split, reverse stock split, stock
dividend,  recapitalization  or similar  corporate  event or  converted  into or
exchanged for cash or other securities as a result of a merger, consolidation or
reorganization  or a dividend in cash or property  (other than an ordinary  cash
dividend after the Company has become public) is made to the stockholders of the
Company, the Board shall make such adjustments in the number and class of shares
of stock or other securities  subject to the Option, and such adjustments to the
exercise  price of  outstanding  Options as it  determines  to be equitable  and
appropriate in its good faith judgment under the circumstances.  In the event of

                                       4
<PAGE>
a merger, consolidation, corporate reorganization or a recapitalization to which
the Company is a party that involves any change in the number or class of shares
of capital  stock of the Company  outstanding,  the Option shall  thereafter  be
exercisable  only  for  and to the  extent  of the  kind  and  amount  of  cash,
securities and/or other property, or the cash equivalent thereof,  receivable as
a result of such  event by the holder of a number of Shares for which the Option
could have been exercised immediately prior to such event (taking account of all
Shares issuable under the Option, whether or not then exercisable).

          (b) The following  rules shall apply in  connection  with Section 9(a)
above:

               (i) no fractional  shares shall be issued as a result of any such
adjustment,  and any fractional shares resulting from the computations  pursuant
to Section 9(a) shall be eliminated without consideration from the Option;

               (ii) no adjustment shall be made for the issuance to stockholders
of rights to subscribe for additional Shares or other securities; and

               (iii) any  adjustments  referred to in Section 9(a) shall be made
by the Board in its reasonable discretion and shall be conclusive and binding on
the Optionee.

     10. Notices. All notices, claims, certificates, requests, demands and other
communications  hereunder  shall be in writing  and shall be deemed to have been
duly  given and  delivered  if  personally  delivered  or if sent by  nationally
recognized  overnight  courier by telecopy or by registered  or certified  mail,
return receipt requested and postage prepaid, addressed as follows:

          (a)      if to the Company, at:

                   Empyrean Bioscience, Inc.
                   23800 Commerce Park Road, Suite A
                   Cleveland, Ohio 44122
                   Attention: Mr. Richard C. Adamany
                   Facsimile No.: (216) 360-7909

                   with a copy to:

                   Kaye, Scholer, Fierman, Hays & Handler, LLP
                   425 Park Avenue
                   New York, New York 10022
                   Attention: Richard H. Kronthal, Esq.
                   Facsimile No.:  212-836-8689

                                       5
<PAGE>
          (b)      if to the Optionee, at:

                   International Bioscience Corporation
                   777 South Flagler Drive
                   Phillips Point Building
                   East Tower, Suite 909
                   West Palm Beach, Florida 33401
                   Attn: Ms. Sara Gomez de Ferro
                   Facsimile No.: (561) 366-8905

                   with a copy to:

                   Holtzman, Krinzman, Equels & Furia
                   2601 South Bayshore Drive, Suite 600
                   Miami, Florida 33133
                   Attn: Mr. Arthur J. Furia, Esq.
                   Facsimile No.: (305) 859-9996

Any such notice or  communication  shall be deemed to have been  received (i) in
the case of personal delivery,  on the date of such delivery (or if such date is
not a business day, on the next  business day after the date sent),  (ii) in the
case of nationally-recognized  overnight courier, on the next business day after
the date sent, (iii) in the case of telecopy transmission,  when received (or if
not sent on a business day, on the next  business day after the date sent),  and
(iv) in the case of mailing,  on the third  business day  following  the date on
which the piece of mail containing such communication is posted.

     11.  Waiver  of  Breach.  The  waiver  by  either  party of a breach of any
provision  of this  Agreement  must be in  writing  and shall not  operate or be
construed as a waiver of any other or subsequent  breach.  Any of the provisions
of this Agreement may be waived only by an instrument in writing executed by the
party or parties whose rights are being waived.

     12.  Optionee's  Undertaking.  The Optionee  hereby agrees to take whatever
additional actions and execute whatever additional  documents the Company may in
its  reasonable  judgment  deem  necessary or advisable in order to carry out or
effect one or more of the  obligations or  restrictions  imposed on the Optionee
pursuant to the provisions of this Agreement.

     13. Amendment. This Agreement may not be amended, terminated,  suspended or
otherwise  modified  except  in a  written  instrument,  duly  executed  by both
parties.  Waivers of or amendments to this Agreement shall be binding as against
the Company only if approved by the Board.

     14.  Governing Law. (i) This Agreement  shall be governed by, and construed
in accordance with, the laws of the State of Florida regardless of the laws that
might otherwise govern under applicable principles of conflicts of law thereof.

                                       6
<PAGE>
          (ii) Except for actions  brought for wrongful  termination  or to seek
termination  of  this  Agreement,  if  any  disagreement  arises  regarding  the
interpretation  of any points of the  Agreement  or any other  point not covered
herein or any claims for damages or specific performance, the disagreement, upon
request of either party hereto delivered in writing to the other party, shall be
resolved  by  arbitration  before a single  arbitrator  in  accordance  with the
commercial   rules  and  procedures  set  forth  by  the  American   Arbitration
Association.  The  prevailing  party  in such  action  or  arbitration  shall be
entitled to receive  from the other party a reasonable  sum for it's  attorneys'
fees and all other  reasonable  costs and  expenses  incurred  in such action or
arbitration.

          (iii) The venue of any arbitration between the parties arising from or
related to this  Agreement  shall be in either  Miami-Dade  County or Palm Beach
County,  Florida. Any litigation arising from or related to this Agreement shall
be brought  exclusively in an  appropriate  state or federal court in Miami-Dade
County  or Palm  Beach  County,  Florida,  and the  parties  waive  any right to
challenge such venue.

     15.   Counterparts.   This  Agreement  may  be  executed  in  one  or  more
counterparts,  and each such counterpart shall be deemed to be an original,  but
all such counterparts together shall constitute but one agreement.

     16. Entire Agreement.  This Agreement is the sole and complete statement of
the parties of their rights and  obligations  with respect to the subject matter
hereof.  This  Agreement is an integrated  agreement and replaces and supersedes
any and all previous obligations and agreements between the parties. The parties
hereto recognize and agree that no  representations or warranties have been made
except as set forth in this  Agreement.  Except as may  otherwise  be  expressly
provided herein,  by signing this Agreement the parties  expressly  release each
other from any and all existing  obligations  that pre-date this Agreement as if
such obligations have been fully performed and satisfied.

     17.  Severability.  In the event any provision of this  Agreement  shall be
held to be invalid,  illegal or unenforceable,  the remaining terms shall remain
in full force and effect,  to effectuate  this Agreement in accordance  with its
intent.  Headings,  title and subtitles of this Agreement are for convenience of
reference  only and are not to be  considered  in  construing  the terms of this
Agreement.

     18. Successors and Assigns.  This Agreement shall be binding upon and inure
to the  benefit  of the  parties  hereto  and their  respective  successors  and
assigns, subject to the limitations set forth in Section 8 hereof.

                     [Remainder of Page Intentionally Blank]

                                       7
<PAGE>
     IN WITNESS  WHEREOF,  the  parties  hereto do hereby  sign,  enter into and
acknowledge this  Nonqualified  Stock Option Agreement on the date first written
above.

                                        INTERNATIONAL BIOSCIENCE CORPORATION

                                        By:_____________________________________

                                        Title:__________________________________

                                        EMPYREAN BIOSCIENCE, INC.

                                        By:_____________________________________

                                        Title:__________________________________

                                       8VOTING AGREEMENT

     VOTING  AGREEMENT  (this  "Agreement")  dated as of August 9, 2000,  by and
between Lawrence D. Bain ("Bain") and International  Bioscience  Corporation,  a
Florida corporation ("IBC").

                                WITNESSETH THAT:

     WHEREAS,  Empyrean  Bioscience,  Inc., a Wyoming corporation  ("Empyrean"),
issued 5,000,000  shares (the "Shares") of its duly  authorized,  fully paid and
non-assessable  common  stock,  no par value,  to IBC  pursuant to the terms and
provisions  of  that  certain  Joint  Venture   Agreement  (the  "Joint  Venture
Agreement")  dated as of  August 9,  2000,  between  IBC and  Empyrean  and,  in
addition,  has entered into a Nonqualified  Stock Option  Agreement (the "Option
Agreement")  dated as of August 9,  2000  with  IBC,  granting  IBC an option to
purchase an additional  2,226,000 shares of Empyrean's common stock (if and when
exercised, the "Option Shares"); and

     WHEREAS,  IBC has agreed that it will be in its best  interests  and in the
best  interest  of  Empyrean  and Bain if Bain,  as a  holder  of  approximately
2,725,000  shares of common  stock of  Empyrean  (together  with any  additional
shares of capital stock of Empyrean Bain directly or indirectly  acquires in the
future,  the "Bain Shares"),  and IBC enter into this Agreement,  subject to the
terms and conditions set out herein; and

     WHEREAS,  Empyrean would not have issued any of its common stock or entered
into the Joint Venture  Agreement or the Option  Agreement with IBC without this
Agreement being entered into.

     NOW,  THEREFORE,  to  induce  Empyrean  and  IBC  to  enter  into,  and  in
consideration of their entering into, the Joint Venture Agreement and the Option
Agreement,  and  in  consideration  of the  promises  and  the  representations,
warranties and agreements contained herein, the parties hereto agree as follows:

     1.  Representations  and  Warranties  of IBC.  IBC  hereby  represents  and
warrants to Bain as of the date hereof as follows:

          (a) AUTHORITY;  NO CONFLICTS.  IBC has the necessary  legal  capacity,
power and  authority  to execute  and  deliver  this  Agreement,  to perform its
obligations  hereunder and to consummate the transactions  contemplated  hereby.
This Agreement has been duly authorized, executed and delivered by and on behalf
of IBC,  and,  assuming  due  authorization,  execution  and  delivery  by Bain,
constitutes  a legal,  valid  and  binding  obligation  of IBC,  enforceable  in
accordance with its terms.  None of the execution and delivery of this Agreement
by and on behalf  of IBC,  the  consummation  of the  transactions  contemplated
hereby and compliance with the terms hereof by IBC will conflict with, or result
<PAGE>
          in any violation  of, or default  (with or without  notice or lapse of
time or both)  under  any  provision  of,  any trust  agreement,  loan or credit
agreement,   note,  bond,  mortgage,   indenture,   lease  or  other  agreement,
instrument,  permit,  concession,  franchise,  license, judgment, order, notice,
decree,  statute,  law,  ordinance,  rule or regulation  applicable to IBC or to
IBC's property or assets.  (b) The Shares.  IBC is the  beneficial  owner of the
Shares and has the sole right and power to vote and dispose of the  Shares,  and
none  of the  Shares  is  subject  to  any  voting  trust  or  other  agreement,
arrangement  or restriction  with respect to the voting or transfer  (other than
the  provisions  of  the  Securities  Act)  of  any of  the  Shares,  except  as
contemplated by this Agreement.

     2.  REPRESENTATIONS  AND WARRANTIES OF BAIN.  Bain  represents and warrants
that this Agreement has been duly authorized, executed and delivered by him and,
assuming due authorization,  execution and delivery by IBC, constitutes a legal,
valid and binding obligation of Bain enforceable in accordance with its terms.

                                       2
<PAGE>
     3. Covenants of IBC. Until the  termination of this Agreement in accordance
with Section 4 hereof, IBC agrees as follows:

          (a) VOTING OF SHARES AND OPTION SHARES. At any meeting of stockholders
of Empyrean or at any  adjournment  thereof or in any other  circumstances  upon
which IBC's vote,  consent or other  approval  as a  stockholder  of Empyrean is
sought,  IBC shall vote the Shares and Option Shares in  accordance  with and in
the same manner as Bain votes the Bain Shares.

          (b)  PROXIES.  As security  for the  agreements  of IBC  provided  for
herein,  IBC  hereby  grants,  contemporaneously  with  the  execution  of  this
Agreement,  to Bain a proxy,  in the form attached  hereto as Exhibit A, to vote
the Shares and Option Shares as indicated in Section 3(a) above. IBC agrees that
this proxy shall be  irrevocable  during the term of this  Agreement and coupled
with an interest and IBC and Bain will take such further  action or execute such
other instruments as may be necessary to effectuate the intent of this PROXY.

          (c) NO  TRANSFER  RESTRICTIONS.  IBC shall be free at any time to sell
any or all of the Shares or Option  Shares to third  parties,  whether by public
resale pursuant to an effective  registration statement or pursuant to any valid
exemption from the registration  requirements under applicable federal and state

                                       3
<PAGE>
securities laws. This Agreement shall immediately  terminate with respect to any
such  shares  sold,  devised,  assigned or  otherwise  disposed of to such third
parties upon  receipt by Bain of a legal  opinion to the effect that such shares
were sold pursuant to a public  resale on Form S-4 or on any other  registration
statement as Empyrean  shall be qualified to file with respect to such shares or
that such transfer is not required to be registered  under the Securities Act of
1933, as amended;  provided,  however,  that this Agremeent  shall not terminate
with respect to those  shares sold in a private sale of Shares or Option  Shares
that, within a 90-day period,  exceed the greater of (i) twenty percent (20%) of
the  total  shares  of  common  stock  then  owned by IBC or (ii) a value of one
million  dollars  (US$1,000,000).   In  the  event  IBC  acquires,  directly  or
indirectly,  any additional  shares of capital stock of Empyrean during the term
of  this  Agreement  through  the  exercise  of any  options  under  the  Option
Agreement, such shares shall immediately become subject to this agreement.

          (d) NO ADDITIONAL AGREEMENTS.  IBC agrees not to enter into any voting
arrangement  or  understanding  with  respect  to the  Shares or Option  Shares,
whether by proxy,  voting agreement or otherwise,  or take any action that would
reasonably  be  expected  to  make  any of  its  representations  or  warranties
contained  herein  untrue or incorrect or could have the effect of preventing or
disabling IBC from performing any of its obligations hereunder.

     4. Term and Termination.

                                       4
<PAGE>
          (a) In the event  that Bain shall  cease to act as a  director  on the
board of  directors  of Empyrean  for any reason,  including by reason of death,
incapacity or resignation, Bain shall, in his sole discretion, either (i) assign
all of his rights and  obligations  relating  to this Voting  Agreement  and the
irrevocable  proxy  granted  to Bain by IBC  pursuant  to  Section  3(b) of this
Agreement  and all voting rights in and a proxy with respect to the Bain Shares,
which  shares  shall be equal to or greater than the number of shares of capital
stock of Empyrean Bain holds as of the date hereof, to the then-current chairman
of the board of  directors of Empyrean as Bain's  successor-in-interest  to this
Agreement  or (ii) elect not to assign his  rights  and  obligations  under this
Agreement to such person, thereby resulting in the termination of this Agreement
and all of the rights and obligations of the parties hereunder. In the event the
number of shares Bain holds at the time he ceases to be a director shall be less
than the number of shares he holds as of the date hereof,  this Voting Agreement
shall  terminate at such time with  respect to the Shares and the Option  Shares
along with all the rights and obligations of the parties hereunder. The right of
Bain to assign the proxy to vote the Shares and Option  Shares,  as described in
Section 4(a)(i) above, shall be a personal right and may not be assigned by Bain
to any other person.

          (b)   Notwithstanding   Section  4(a)  above,   this  Agreement  shall
terminate,  and no party shall have any rights or obligations hereunder and this
Agreement  shall  become  null and void and have no further  effect  immediately
following such time as Empyrean  becomes the full legal and beneficial  owner of
100% of its issued and outstanding capital stock.

     5. General Provisions.

          (a)  INTERPRETATION.  When a reference  is made in this  Agreement  to
Sections,  such  reference  shall  be to a  Section  of  this  Agreement  unless
otherwise indicated.  The headings contained in this Agreement are for reference
purposes only and shall not affect in any way the meaning or  interpretation  of
this Agreement. Wherever the words "include," "includes" or "including" are used
in this  Agreement,  they shall be deemed to be followed  by the words  "without
limitation."

          (b)  COUNTERPARTS.  This  Agreement  may be  executed  in one or  more
counterparts,  all of which shall be considered one and the same agreement,  and
shall become effective when one or more of the counterparts  have been signed by
each of the parties and delivered to the other parties, it being understood that
each party need not sign the same counterpart.

                                       5
<PAGE>
          (c)  GOVERNING  LAW.  (i) This  Agreement  shall be  governed  by, and
construed in accordance with, the laws of the State of Wyoming regardless of the
laws that might otherwise govern under applicable principles of conflicts of law
thereof.

               (ii) Except for actions  brought for wrongful  termination  or to
seek  termination of this Agreement,  if any  disagreement  arises regarding the
interpretation  of any points of the  Agreement  or any other  point not covered
herein or any claims for damages or specific performance, the disagreement, upon
request of either party hereto delivered in writing to the other party, shall be
resolved  by  arbitration  before a single  arbitrator  in  accordance  with the
commercial   rules  and  procedures  set  forth  by  the  American   Arbitration
Association.  The  prevailing  party  in such  action  or  arbitration  shall be
entitled to receive  from the other party a reasonable  sum for it's  attorneys'
fees and all other  reasonable  costs and  expenses  incurred  in such action or
arbitration.

               (iii) The venue of any  arbitration  between the parties  arising
from or related to this Agreement shall be in either  Miami-Dade  County or Palm
Beach County,  Florida. Any litigation arising from or related to this Agreement
shall  be  brought  exclusively  in an  appropriate  state or  federal  court in
Miami-Dade County or Palm Beach County, Florida, and the parties waive any right
to challenge such venue.

          (d)  COMPLETE  AGREEMENT.  This  Agreement  is the sole  and  complete
statement  of the parties of their  rights and  obligations  with respect to the
subject  matter hereof.  This Agreement is an integrated  agreement and replaces
and  supersedes  any and all previous  obligations  and  agreements  between the
parties.  The parties  hereto  recognize  and agree that no  representations  or
warranties have been made except as set forth in this  Agreement.  Except as may
otherwise be expressly  provided  herein,  by signing this Agreement the parties
expressly release each other from any and all existing obligations that pre-date
this Agreement as if such  obligations  have been fully performed and satisfied.
Any  amendments  to this  Agreement  shall be in writing  and  executed  by both
parties hereto.

                [REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK]

                                       6
<PAGE>
     IN WITNESS  WHEREOF,  the  parties  hereto do hereby  sign,  enter into and
acknowledge this Agreement on the date first written above.

                                        INTERNATIONAL BIOSCIENCE CORPORATION

                                        By:_____________________________________

                                        Title:__________________________________

                                        ----------------------------------------
                                        Lawrence D. Bain
<PAGE>
                                    Exhibit A

Power of Attorney and Irrevocable Proxy

     Reference  is hereby made to that  certain  Voting  Agreement  (the "Voting
Agreement"),  dated as of the date  hereof,  between the  undersigned,  IBC (the
"Granting Stockholder"), and Lawrence D. Bain (the "Proxyholder"),  with respect
to certain shares of common stock of Empyrean Bioscience,  Inc. owned by IBC, of
which this Power of Attorney and Irrevocable  Proxy (this  "Irrevocable  Proxy")
forms a part.  Capitalized  terms used but not defined in this Irrevocable Proxy
have the  respective  meanings  ascribed to such terms in the Voting  Agreement.
This Irrevocable Proxy is being delivered by the Granting  Stockholder  pursuant
to Section 3(b) of the Voting Agreement.

     The  undersigned  Granting  Stockholder  hereby  irrevocably  appoints  the
Proxyholder as the Granting Stockholder's attorney-in-fact and proxy pursuant to
the provisions of Section  17-16-722 of the Wyoming  Business  Corporation  Act,
with full power of substitution,  in the Granting  Stockholder's name, place and
stead,  to vote and otherwise act (by written consent or otherwise) with respect
to all  Shares  and  Option  Shares,  now  or  hereafter  owned,  of  record  or
beneficially,  by the Granting  Stockholder,  which the Granting  Stockholder is
entitled to vote at any meeting of the stockholders of Empyrean  (whether annual
or special and whether or not an adjourned  or postponed  meeting) or consent in
lieu of any such meeting or otherwise.  A copy of the executed Voting  Agreement
is attached hereto and is made a part of and incorporated into this Proxy.

     THIS POWER OF ATTORNEY AND  IRREVOCABLE  PROXY IS  IRREVOCABLE  AND COUPLED
WITH AN  INTEREST,  SUCH  INTEREST  BEING THE  VOTING  AGREEMENT.  The  Granting
Stockholder hereby revokes all other proxies and powers of attorney with respect
to the  Shares  and  Option  Shares  that  the  Granting  Stockholder  may  have
heretofore granted,  and no subsequent proxy or power of attorney shall be given
or written consent  executed (and if given or executed,  shall not be effective)
by the  Granting  Stockholder  with respect  thereto.  In the event the Granting
Stockholder acquires,  directly or indirectly,  any additional shares of capital
stock of  Empyrean  during  the term of the Voting  Agreement  as  described  in
Section 3(c)  thereof,  such shares  shall  immediately  become  subject to this
irrevocable proxy.

     This Irrevocable  Proxy shall be valid and irrevocable  until terminated in
accordance with the conditions set forth below:

     (a) In the event that the  Proxyholder  shall cease to act as a director on
the board of directors of Empyrean for any reason, including by reason of death,
incapacity or resignation, the Proxyholder shall, in his sole discretion, either
(i) assign all of his rights and  obligations  relating to the Voting  Agreement
and the irrevocable proxy granted to the Proxyholder by the Granting Stockholder
pursuant to Section 3(b) of the Voting  Agreement and all voting rights in and a
proxy with respect to the Bain Shares, which shares shall be equal to or greater
than the number of shares of capital stock of Empyrean the Proxyholder  holds as
of the date hereof,  to the  then-current  chairman of the board of directors of
Empyrean as the Proxyholder's  successor-in-interest  to the Voting Agreement or
(ii) elect not to assign his rights and obligations  under the Voting  Agreement
to such person, thereby resulting in the termination of the Voting Agreement and
all of the rights and  obligations  of the parties  hereunder.  In the event the
number of shares  the  Proxyholder  holds at the time he ceases to be a director
shall be less than the  number of  shares  he holds as of the date  hereof,  the
Voting Agreement shall terminate at such time with respect to the Shares and the
Option  Shares  along  with  all  the  rights  and  obligations  of the  parties
hereunder.  The right of the  Proxyholder to assign the proxy to vote the Shares
and Option Shares,  as described in Section  4(a)(i) above,  shall be a personal
right and may not be assigned by Proxyholder to any other person.

     (b)  Notwithstanding  paragraph  (a)  above,  the  Voting  Agreement  shall
terminate,  and no party shall have any rights or obligations  hereunder and the
Voting  Agreement  shall  become  null  and  void  and  have no  further  effect
immediately  following  such  time  as  Empyrean  becomes  the  full  legal  and
beneficial owner of 100% of its issued and outstanding capital stock.

     (c) The Voting  Agreement shall  immediately  terminate with respect to any
such Shares or Option Shares sold, devised, assigned or otherwise disposed of by
the Granting  Stockholder to a third party upon receipt by the  Proxyholder of a
legal  opinion to the effect  that such  shares  were sold  pursuant to a public
resale on Form S-4 or on any other  registration  statement as Empyrean shall be
qualified  to file with  respect  to such  shares or that such  transfer  is not
required  to be  registered  under  the  Securities  Act of  1933,  as  amended;
provided, however, that the Voting Agremeent shall not terminate with respect to
those  Shares or Option  Shares sold in a private  sale of such Shares or Option
Shares that,  within a 90-day  period,  exceed the greater of (i) twenty percent
(20%) of the total shares of common stock then owned by the Granting Stockholder
or (ii) a value of one million dollars (US$1,000,000).

Dated as of August 9, 2000

                                        INTERNATIONAL BIOSCIENCE CORPORATION

                                         By:______________________________

                                         Name:__________________________________

                                         Title:_________________________________

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00014-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00014-of-00352.parquet"}]]